Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has granted accelerated approval to neladalkib (Nelkarmi) for patients with ALK-positive non-small cell lung cancer (NSCLC) who've already been treated with prior ALK-directed therapies. The approval is backed by the ALKOVE-1 trial, which showed meaningful response rates even in heavily pretreated patients. A phase 3 trial comparing neladalkib to alectinib in treatment-naïve patients is now underway.
The FDA has granted accelerated approval to neladalkib (Nelkarmi) for patients with unresectable locally advanced or metastatic ALK-positive NSCLC who have previously been treated with alectinib, or with two or more ALK-directed TKIs plus platinum-based chemotherapy. The decision was supported by data from the phase 1/2 ALKOVE-1 trial, making neladalkib a new option for a patient population with limited alternatives after prior targeted therapy.
In the ALKOVE-1 trial, patients previously treated with alectinib (n=67) achieved a 49% overall response rate (ORR), while the more heavily pretreated group (n=155) achieved a 32% ORR — with durable responses lasting well beyond six months in both cohorts. The drug's safety profile was notable for liver enzyme elevations, though these were largely asymptomatic, transient, and manageable with dose adjustments.
By the Numbers:
Why it matters: ALK-positive NSCLC patients who progress on multiple prior TKIs have very few effective options. Neladalkib fills a critical gap, offering durable responses even in heavily pretreated patients, while an ongoing phase 3 trial (ALKAZAR) could eventually position it as a first-line standard of care.